GSK vs. PCVX: GSK vs. Vaxcyte Stock Comparison

Company Profile

GSK (GSK) and Vaxcyte (PCVX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but GSK is classified in Pharmaceuticals while PCVX is classified in Biotechnology.

GSK (GSK) has more than two decades of public-market history since March 28, 1980, whereas Vaxcyte (PCVX) listed on June 12, 2020 and has a much shorter record to draw on.

Vaxcyte (PCVX) trades as ordinary local shares, while GSK (GSK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Vaxcyte (PCVX) reports a negative ROE of -42.68%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile GSK (GSK) reports 28.27%, ranking against industry peers normally.

GSK (GSK) at 12.97% retains a top-quartile share of revenue as profit, ahead of Vaxcyte (PCVX) at 0.00%, which keeps about the industry-typical share.

GSK (GSK) at 32.14% operates in the top operating margin quartile, ahead of Vaxcyte (PCVX) at 0.00%, which runs around its industry’s norm.

Profitability Metrics

Growth

Only one side can be read here: GSK (GSK) reports revenue growth of 4.11%, ranked against its industry; Vaxcyte (PCVX) has no revenue growth figure this period.

Only one side can be read here: GSK (GSK) reports EPS growth of 123.15%, ranked against its industry; Vaxcyte (PCVX) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Vaxcyte (PCVX) at 4.56 keeps current ratio within its industry’s typical mid-range, while GSK (GSK) at 0.86 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GSK.

Vaxcyte (PCVX) at 0.09 carries an industry-typical debt-to-equity mix, while GSK (GSK) at 1.30 uses more debt funding than most peers.

Financial Strength Metrics

Dividends

Vaxcyte (PCVX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a yield of 1.57%, ranking against industry peers normally.

Vaxcyte (PCVX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile GSK (GSK) reports a payout of 63.33%, ranking against industry peers normally.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: GSK (GSK) trades at 17.54 times trailing earnings, ranked against its peers, while Vaxcyte (PCVX) has no P/E ratio this period.

A sales-based read is only available for GSK (GSK), whose P/S ratio of 3.01 ranks against industry peers; Vaxcyte (PCVX) reports no figure this period.

On P/B ratio, both GSK (GSK) at 4.02 and Vaxcyte (PCVX) at 3.83 are valued close to their industries’ norm against book — neither stands out from peers.

Valuation Metrics